Præcisering af forventningerne til 2022 og udmelding af forventningerne for 2023
Selskabsmeddelelse nr. 1/2023
Holbæk, den 12. januar 2023
Præcisering af forventningerne til 2022 og udmelding af forventningerne for 2023
Forventningerne til årets resultat før skat indsnævres fra intervallet 450-510 mio. kr. til 478-482 mio. kr.
Årsrapporten for 2022 offentliggøres som tidligere udmeldt den 10. februar 2023.
I 2023 forventer sparekassen en fortsat stærk udvikling i basisindtjeningen samt usikkerhed i forhold til aktivitetsniveauet og nedskrivninger.
Resultat før skat for 2023 forventes på denne baggrund i intervallet DKK 500-600 mio. kr.
Med venlig hilsen
Lars Petersson Thomas Kullegaard
Administrerende direktør Formand
Yderligere information:
Presse- og direktionsrådgiver Morten Huse Eikrem-Jeppesen, tlf. 53 85 07 70
Administrerende direktør Lars Petersson
Sparekassedirektør Lars Bolding
Vedhæftet fil
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
RESULT OF RIKSBANK CERTIFICATE SALE7.5.2024 10:15:00 CEST | Press release
AuctionAuction resultsAuction date2024-05-07Start date2024-05-08Maturity date2024-05-15Interest rate4.00 %Offered volume, SEK bn947.0Total bid amount, SEK bn818.0Accepted volume, SEK bn818.0Number of bids20Percentage allotted, %100.00
Ekstraordinære indfrielser (CK93)7.5.2024 10:00:00 CEST | pressemeddelelse
KommuneKredit offentliggør hermed oplysninger om ekstraordinære indfrielser (CK93) pr. 3. maj 2024. Der er pr. opgørelsesdagen ingen ekstraordinære indfrielser. For yderligere informationer om dataformat og –indhold henvises til Nasdaqs hjemmeside. Med venlig hilsen KommuneKredit
DSV, 1106 - SHARE BUYBACK IN DSV A/S7.5.2024 09:53:54 CEST | Press release
Company Announcement No. 1106 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-3145,0001,013.69146,985,0504:29 April 202475,0001,014.7176,103,2505:30 April 20247,0001,002.427,016,9406:1 May 20249,680993.049,612,6277:2 May 20247,320990.197,248,1918:3
Coloplast Finance B.V. - Interim Financial Report, H1 2023/247.5.2024 09:51:03 CEST | Press release
H1 2023/24 Interim financial results, H1 2023/24 1 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin1) of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional Urology 5%.Continued good momentum in Chronic Care. Ostomy Care growth was driven by broad-based contribution from Emerging markets and Europe, compensating for lower growth in the US which was held back by order phasing and now expected to be H2 weighted. Continence Care growth was driven by intermittent catheters, including good contribution from LujaTM. Voice and Respiratory Care had a strong Q2, driven by double-digit growth in both laryngectomy and tracheostomy.Growth in Advanced Wound Dressings was broad-based
Suspension af udvalgte afdelinger i Værdipapirfonden Sparinvest fortsætter den 7. maj 20247.5.2024 09:44:09 CEST | pressemeddelelse
Det skal oplyses, at suspension af nedenstående afdelinger forlænges i dag den 7. maj 2024. Suspensionen vil blive ophævet, når der igen kan stilles korrekt indre værdi i de enkelte afdelinger. ISINOrder book codeAfdelingsnavn før ændringAfdelingsnavn efter ændringDK0060254043SPVINONye obligationsmarkederINDEX Emerging Market Bonds LokalvalutaDK0060254126SPVINOAKKKLANye obligationsmarkeder Akk. – KL AINDEX Emerging Market Bonds Lokalvaluta Akk. – KL A Suspensionen kommer i forlængelse af den udmeldte og planlagte omlægning i foreningen jf. børsmeddelelser fra den 19. april 2024 og 1. maj. Eventuel henvendelse vedrørende denne meddelelse kan rettes til npa.pm@nykredit.dk cc jna@nykredit.dk. Med venlig hilsen Morten Skipper Direktør, ID-Sparinvest, Filial af Sparinvest S.A., Luxembourg